MUC1/CA 15-3 is used as a serological clinical marker of breast cancer to monitor response to breast cancer treatment and disease recurrence. Most antibodies target the highly immunodominant core peptide domain of 20 amino acid (APDTRPAPGSTAPPAHGVTS) tandem repeats. Some antibodies recognize glycosylated epitopes.
| Inventor | Institute |
|---|---|
| Mike Price | University of Nottingham |
| Cat. #: | 153396 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Cancer types: | Breast cancer;Gynaecologic cancer |
| Research Fields: | Cancer;Cell biology;Genetics |
| Application: | ELISA ; FACS ; IHC ; WB |
| Target: | MUC1 |
| Reactivity: | Human |
| Clone: | C595 (NCRC48) |
| Host: | Mouse |
| Class: | Monoclonal |
| Alternate name: | CD227; KL6; Mucin 1; PEMT |
|---|---|
| Product description: | MUC1/CA 15-3 is used as a serological clinical marker of breast cancer to monitor response to breast cancer treatment and disease recurrence. Decreased levels over time may be indicative of a positive response to treatment. Conversely, increased levels may indicate disease progression. At an early stage disease, only 21% of patients exhibit high MUC1/CA 15-3 levels, that is why CA 15-3 is not a useful screening test. Most antibodies target the highly immunodominant core peptide domain of 20 amino acid (APDTRPAPGSTAPPAHGVTS) tandem repeats. Some antibodies recognize glycosylated epitopes. Medullary cystic kidney disease 1. |
| Conjugation: | Unconjugated |
| Isotype: | IgG3 |
| Molecular weight: | 122 kDa |
| Immunogen: | Urinary MUC-1 mucin (Human) |
| Target background: | MUC1/CA 15-3 is used as a serological clinical marker of breast cancer to monitor response to breast cancer treatment and disease recurrence. Decreased levels over time may be indicative of a positive response to treatment. Conversely, increased levels may indicate disease progression. At an early stage disease, only 21% of patients exhibit high MUC1/CA 15-3 levels, that is why CA 15-3 is not a useful screening test. Most antibodies target the highly immunodominant core peptide domain of 20 amino acid (APDTRPAPGSTAPPAHGVTS) tandem repeats. Some antibodies recognize glycosylated epitopes. Medullary cystic kidney disease 1. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 0.9-1.1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -80° C |
| Shipping conditions: | Dry ice |
| References: |
Yew et al. 2013. PLoS One. 8(9):e72637. PMID: 24039787. Epimorphin-induced MET sensitizes ovarian cancer cells to platinum. Guimaraes-Souza et al. 2012. Nephrol Dial Transplant. 27(8):3082-90. PMID: 22287659. In vitro reconstitution of human kidney structures for renal cell therapy. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151017 | Anti-MBP [R29.6] |
Key Info
Anti-MBP [R29.6]
|
View Tool | |||||||||||||||||||
| 151025 | Anti-Vascular endothelium [10] |
Key Info
Anti-Vascular endothelium [10]
|
View Tool | |||||||||||||||||||
| 151028 | Anti-Cytochrome P450 2C2, 2B1/2 [h7] |
Key Info
Anti-Cytochrome P450 2C2, 2B1/2 [h7]
|
View Tool | |||||||||||||||||||
| 151029 | Anti-HSVICP8 [11E2] |
Key Info
Anti-HSVICP8 [11E2]
|
View Tool | |||||||||||||||||||
| 151037 | Anti-Cdk1 [17 (A17)] |
Key Info
Anti-Cdk1 [17 (A17)]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.